ProMIS Neurosciences Inc Dossier
Qualitative Analysis
Business overview
ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company focused on the discovery and development of antibody therapeutics and therapeutic vaccines selectively targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). The company utilizes its proprietary thermodynamic, computational discovery platform, EpiSelect™ (formerly ProMIS and Collective Coordinates), to predict and identify Disease Specific Epitopes (DSEs) uniquely exposed on the molecular surface of misfolded proteins. This precision approach allows ProMIS to design antibodies that target toxic soluble oligomers while sparing non-toxic monomers and plaque, potentially reducing off-target side effects such as amyloid-related imaging abnormalities (ARIA).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Rigorous execution and data integrity maintenance in the ongoing PRECISE-AD Phase 1b clinical trial for lead candidate PMN310, a monoclonal antibody selectively targeting toxic amyloid-beta oligomers in Alzheimer's disease.
Expected impact: Establish a differentiated safety and efficacy profile relative to plaque-directed antibodies by selectively targeting toxic oligomers while sparing plaque.
Evaluating partnership and business development opportunities with potential strategic collaborators to maximize value from the company's pipeline and secure non-dilutive funding.
Expected impact: Secure strategic collaborations and non-dilutive funding to extend the company's cash runway and support pipeline development.